| scholarly article | Q13442814 |
| P50 | author | Julia Santos | Q58331172 |
| P2093 | author name string | Qing Zhong | |
| Renu A Kowluru | |||
| P2860 | cites work | Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression | Q79377409 |
| Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy | Q79855571 | ||
| Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC | Q80025376 | ||
| Isolation of MMP-2 from MMP-2/TIMP-2 complex: characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane | Q80579068 | ||
| Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes | Q80738371 | ||
| Role of matrix metalloproteinase-9 in endothelial apoptosis in chronic heart failure in mice | Q81008508 | ||
| Oxidative stress activates MMP-2 in cultured human coronary smooth muscle cells | Q81543021 | ||
| Matrix metalloproteinase-9 activity in human lens epithelial cells of cortical, posterior subcapsular, and nuclear cataracts | Q82698337 | ||
| Connective tissue growth factor and tissue inhibitor of matrix metalloproteinase-2 in patients with exfoliative glaucoma | Q84139583 | ||
| Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory | Q24647760 | ||
| The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded | Q24811354 | ||
| Pericytes: developmental, physiological, and pathological perspectives, problems, and promises | Q27026645 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Tissue inhibitors of metalloproteinases: evolution, structure and function | Q28138083 | ||
| Matrix metalloproteinases | Q28140451 | ||
| Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) | Q28204521 | ||
| Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier | Q28235057 | ||
| Matrix metalloproteinase-9 and autoimmune diseases | Q28237731 | ||
| Leukocyte-mediated endothelial cell injury and death in the diabetic retina | Q28345653 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Matrix metalloproteinases and the regulation of tissue remodelling | Q29618747 | ||
| Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice | Q30466248 | ||
| Development of matrix metalloproteinase inhibitors in cancer therapy. | Q31832006 | ||
| Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes | Q74586672 | ||
| Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial | Q74819291 | ||
| Diabetic retinopathy | Q75217418 | ||
| Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor | Q77334697 | ||
| Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress | Q79173099 | ||
| Matrix metalloproteinases in human diabetic and nondiabetic vitreous | Q32058683 | ||
| Doxycycline-mediated inhibition of choroidal neovascularization | Q33465433 | ||
| Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats | Q33793466 | ||
| MMP-9 and the perioperative management of LASIK surgery | Q33887903 | ||
| MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells | Q33938788 | ||
| Role of vascular endothelial growth factor in diabetic vascular complications | Q34039760 | ||
| Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction | Q34077433 | ||
| Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression | Q34110092 | ||
| Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription | Q34345938 | ||
| Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets | Q34430700 | ||
| Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase | Q34512906 | ||
| Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy | Q34718901 | ||
| Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy | Q34784085 | ||
| Physiology and pathophysiology of matrix metalloproteases. | Q35007715 | ||
| Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy | Q35027703 | ||
| β-Adrenergic Receptor-Stimulated Cardiac Myocyte Apoptosis: Role of β1 Integrins | Q35101542 | ||
| Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. | Q35114385 | ||
| Cell surface association of matrix metalloproteinase-9 (gelatinase B). | Q35144559 | ||
| Epidemiology of diabetic retinopathy. | Q35187082 | ||
| Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. | Q35404674 | ||
| Mitochondrial biogenesis and the development of diabetic retinopathy | Q35457777 | ||
| Diabetic retinopathy, superoxide damage and antioxidants. | Q35545811 | ||
| Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes. | Q35601594 | ||
| Diabetic retinopathy and damage to mitochondrial structure and transport machinery | Q35687928 | ||
| Mitochondrial redox control of matrix metalloproteinases | Q35860310 | ||
| Deadly conversations: nuclear-mitochondrial cross-talk | Q35891836 | ||
| Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling | Q36094362 | ||
| MT1-MMP: a potent modifier of pericellular microenvironment. | Q36141763 | ||
| Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction | Q36175849 | ||
| Transcriptional regulation of matrix metalloprotease gene expression in health and disease | Q36250996 | ||
| Matrix metalloproteinases (MMPs) in health and disease: an overview | Q36348231 | ||
| Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer | Q36471120 | ||
| Regulation of matrix metalloproteinase gene expression | Q36682744 | ||
| Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. | Q36836612 | ||
| Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia | Q36844627 | ||
| Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy | Q37069135 | ||
| Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells | Q37072778 | ||
| Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy | Q37084522 | ||
| Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. | Q37195371 | ||
| Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9 | Q37241389 | ||
| On the pathogenesis of diabetic retinopathy. A 1990 update | Q37341764 | ||
| Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy | Q37356613 | ||
| Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin | Q37384532 | ||
| Matrix metalloproteinases and peripheral arterial disease | Q37559372 | ||
| Multiple roles of metalloproteinases in neurological disorders | Q37829033 | ||
| Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. | Q37852030 | ||
| The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease | Q37917907 | ||
| H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells | Q38510105 | ||
| Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain | Q39323926 | ||
| miR-520c and miR-373 upregulate MMP9 expression by targeting mTOR and SIRT1, and activate the Ras/Raf/MEK/Erk signaling pathway and NF-κB factor in human fibrosarcoma cells | Q39427500 | ||
| Disturbed matrix metalloproteinase activity of Bruch's membrane in age-related macular degeneration. | Q39759898 | ||
| Role of the hemopexin domain of matrix metalloproteinases in cell migration | Q39959867 | ||
| Induction of matrix metalloproteinase gene expression in an endothelial cell line by direct interaction with malignant cells | Q40217561 | ||
| Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis | Q40565710 | ||
| Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies | Q41607468 | ||
| Probing the depths of degradation: matrix metalloproteinase-2 and endometrial menstrual breakdown | Q42355888 | ||
| Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes | Q42803133 | ||
| Role of interleukin-1beta in the pathogenesis of diabetic retinopathy | Q43007582 | ||
| Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy | Q43160577 | ||
| Diabetes-induced mitochondrial dysfunction in the retina | Q44669128 | ||
| Expression profiles of matrix metalloproteinase 9 in teleost fish provide evidence for its active role in initiation and resolution of inflammation | Q44685257 | ||
| A central role for inflammation in the pathogenesis of diabetic retinopathy | Q44961996 | ||
| Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants | Q45124577 | ||
| Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats | Q45161327 | ||
| Aspirin inhibits MMP-2 and MMP-9 expression and activity through PPARalpha/gamma and TIMP-1-mediated mechanisms in cultured mouse celiac macrophages. | Q46001076 | ||
| Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage | Q46152432 | ||
| MMP-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes | Q46163874 | ||
| The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy | Q46247076 | ||
| Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. | Q46774822 | ||
| Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy | Q46874442 | ||
| Inhibition of GSK-3beta mediates expression of MMP-9 through ERK1/2 activation and translocation of NF-kappaB in rat primary astrocyte | Q46904500 | ||
| Production and Activation of Matrix Metalloproteinase-2 in Proliferative Diabetic Retinopathy | Q47952325 | ||
| Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. | Q49133201 | ||
| Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. | Q50468465 | ||
| Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. | Q53617689 | ||
| Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro | Q59200917 | ||
| The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision | Q72759987 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diabetic retinopathy | Q631361 |
| P304 | page(s) | 797-805 | |
| P577 | publication date | 2012-04-23 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9 | |
| P478 | volume | 21 |
| Q58719110 | ATN-161 as an Integrin α5β1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis |
| Q42107211 | Apoptotic effect of mtrix metalloproteinases 9 in the development of diabetic retinopathy |
| Q33598712 | Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes |
| Q28288148 | Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade |
| Q26744760 | Circulating Biomarkers of Diabetic Retinopathy: An Overview Based on Physiopathology |
| Q38508141 | Contribution of epigenetics in diabetic retinopathy |
| Q38784171 | Degradomics in Neurotrauma: Profiling Traumatic Brain Injury |
| Q57478296 | Deletion of RasGRF1 Attenuated Interstitial Fibrosis in Streptozotocin-Induced Diabetic Cardiomyopathy in Mice through Affecting Inflammation and Oxidative Stress |
| Q92130384 | Diabetic Retinopathy, lncRNAs, and Inflammation: A Dynamic, Interconnected Network |
| Q37280210 | Dynamic DNA methylation of matrix metalloproteinase-9 in the development of diabetic retinopathy |
| Q59809200 | Early Enhanced Leucine-Rich -2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice |
| Q54351123 | Ethanol extract of Dendrobium chrysotoxum Lindl ameliorates diabetic retinopathy and its mechanism. |
| Q37250409 | Functional and molecular characterization of ex vivo cultured epiretinal membrane cells from human proliferative diabetic retinopathy. |
| Q41536951 | GYY4137, a Hydrogen Sulfide Donor Modulates miR194-Dependent Collagen Realignment in Diabetic Kidney. |
| Q90324959 | High-glucose-induced changes in macrophage secretome: regulation of immune response |
| Q90161777 | Homocysteine Disrupts Balance between MMP-9 and Its Tissue Inhibitor in Diabetic Retinopathy: The Role of DNA Methylation |
| Q51429794 | Hyperoside ameliorates glomerulosclerosis in diabetic nephropathy by downregulating miR-21. |
| Q36665694 | IL-1β promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-κB- and AP-1-dependent pathways |
| Q37396370 | Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy |
| Q64270971 | Loss of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) in the Diabetic Retina: Role of Matrix Metalloproteinases |
| Q35436829 | Loss of survival factors and activation of inflammatory cascades in brain sympathetic centers in type 1 diabetic mice |
| Q37578873 | Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases |
| Q36088748 | Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients. |
| Q40580698 | Matrix Metalloproteinase-9 -1562C/T Gene Polymorphism Is Associated with Diabetic Nephropathy |
| Q37026766 | Matrix metalloproteinase-9 and vascular endothelial growth factor expression change in experimental retinal neovascularization |
| Q35880955 | Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies |
| Q46578760 | Methylene blue prevents retinal damage in an experimental model of ischemic proliferative retinopathy |
| Q34159541 | Mitochondrial haplogroups are associated with severity of diabetic retinopathy. |
| Q47094741 | NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes. |
| Q90060268 | Network Pharmacology-based Investigation of the Underlying Mechanism of Panax Notoginseng Treatment of Diabetic Retinopathy |
| Q38013679 | Novel targets against retinal angiogenesis in diabetic retinopathy |
| Q64997207 | Nutraceuticals for the Treatment of Diabetic Retinopathy. |
| Q39290391 | Omega-3 fatty acids in prevention of diabetic retinopathy. |
| Q90070032 | Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology |
| Q46248374 | Oxidative stress and reactive oxygen species: a review of their role in ocular disease |
| Q54363541 | Paeoniflorin Suppressed High Glucose-Induced Retinal Microglia MMP-9 Expression and Inflammatory Response via Inhibition of TLR4/NF-κB Pathway Through Upregulation of SOCS3 in Diabetic Retinopathy. |
| Q53161994 | Plasma neutrophil gelatinase-associated lipocalin levels are positively associated with diabetic retinopathy in patients with Type 2 diabetes. |
| Q92527902 | Prospective Application of Activity-Based Proteomic Profiling in Vision Research-Potential Unique Insights into Ocular Protease Biology and Pathology |
| Q37472038 | Purslane (Portulaca oleracea) Seed Consumption And Aerobic Training Improves Biomarkers Associated with Atherosclerosis in Women with Type 2 Diabetes (T2D). |
| Q58762933 | Remodeling of Retinal Architecture in Diabetic Retinopathy: Disruption of Ocular Physiology and Visual Functions by Inflammatory Gene Products and Pyroptosis |
| Q39238324 | Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) axis in the Pathogenesis of Diabetic Retinopathy |
| Q47143565 | STAT3-mediated activation of miR-21 is involved in down-regulation of TIMP3 and neovascularization in the ischemic retina |
| Q34159652 | Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy |
| Q60947291 | Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications |
| Q39402838 | The role and therapeutic potential of melatonin in age-related ocular diseases. |
| Q35031693 | Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO. |
| Q37137887 | Truncated netrin-1 contributes to pathological vascular permeability in diabetic retinopathy |
| Q94665718 | Use of Glycated Hemoglobin (A1c) as a Biomarker for Vascular Risk in Type 2 Diabetes: Its Relationship with Matrix Metalloproteinases-2, -9 and the Metabolism of Collagen IV and Elastin |
| Q37251091 | VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy |
| Q41834250 | α-Mangostin suppresses lipopolysaccharide-induced invasion by inhibiting matrix metalloproteinase-2/9 and increasing E-cadherin expression through extracellular signal-regulated kinase signaling in pancreatic cancer cells |
Search more.